The Role of Alkamides as an Active Principle of Echinacea

Abstract

Alkamides are the major lipophilic constituents of Echinacea preparations, which are widely used in some European countries and in North America for common colds. In earlier investigations they have been shown to possess stimulatory effects on phagocytosis. Recent experiments have demonstrated that alkamides are detectable in human blood in relevant concentrations after oral administration of Echinacea preparations. Alkamides show structural similarity with anandamide, an endogenous ligand of cannabinoid receptors. Consequently, it was found that alkamides bind significantly to CB₂ receptors, which is now considered as a possible molecular mode of action of Echinacea alkamides as immunomodulatory agents. It was also demonstrated recently in several studies that alkamide-containing Echinacea preparations trigger effects on the pro-inflammatory cytokines. They were therefore suggested as a new class of cannabinomimetics. However, the therapeutic relevance of these findings is still not clear as clinical studies on the common cold show contradictory results. Among the many pharmacological properties reported, investigations concerning herb-drug interactions have been neglected for a long time. Latest research concludes that prolonged use of Echinacea poses a minimal risk for co-medications metabolized by the P450 enzymes.

Alkamides - Echinacea purpurea - Echinacea angustifolia - Asteraceae - immunomodulation - pharmacokinetics - cannabinoid receptor binding - herb-drug interactions

References

• 1 Brevoort T. The booming U.S. botanical market.  Herbalgram. 1998;  44 33-46.
• 2 Barrett B. Medicinal properties of Echinacea: a critical review.  Phytomedicine. 2003;  10 66-86.
• 3 Linde K, Barrett B, Woelkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2006 Issue 1.
• 4 Barnes J, Anderson L A, Gibbons S, Phillipson J D. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): A review of their chemistry, pharmacology and clinical properties.  J Pharm Pharmacol. 2005;  57 929-54.
• 5 Bauer R. Chemistry, analysis and immunological investigations of Echinacea phytopharmaceuticals. In: Wagner H, editor Immunomodulatory agents from plants. Basel, Boston, Berlin; Birkhäuser Verlag 1999: 41-88.
• 6 Greger H. Comparative phytochemistry of the alkamides. Amsterdam, Oxford, New York, Tokyo; Elsevier 1988.
• 7 Breyant B P, Mezine I. Alkylamides that produce tingling paresthesia activate tactile and thermal trigeminal neurons.  Brain Res. 1999;  842 452-60.
• 8 Ramsewak R S, Erickson A J, Nair M G. Bioactive N-isobutylamides from the flower buds of Spilanthes acmella .  Phytochemistry. 1999;  51 729-32.
• 9 Bohlmann R, Ziesche J, Robinson H, King R M. Polyacetylene compounds - new amides from Spilanthes alba .  Phytochemistry. 1980;  19 1535-7.
• 10 Perry N B, Van Klink J W, Burgess E J, Parmenter G A. Alkamide levels in Echinacea purpurea: a rapid analytical method revealing differences among roots, rhizomes, stems, leaves and flowers.  Planta Med. 1997;  63 58-62.
• 11 Bauer R, Remiger P, Wagner H. Echinacea. Vergleichende DC- und HPLC-Analyse der Herba-Drogen von Echinacea purpurea, E. pallida und E. angustifolia .  Dtsch Apoth Ztg. 1988;  128 174-80.
• 12 Kabganian R, Carrier D J, Rose P A, Abrams S R, Sokhansanj S. Localization of alkamides, echinacoside and cynarin with Echinacea angustifolia .  J Herbs Spices Med Plants. 2002;  10 73-81.
• 13 Wills R BH, Stuart D L. Alkylamide and cichoric acid levels in Echinacea purpurea grown in Australia.  Food Chem. 1999;  67 385-8.
• 14 Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate TNF-α gene expression via cannabinoid receptor CB₂ and multiple signal transduction pathways.  FEBS Lett. 2004;  577 563-9.
• 15 Woelkart K, Marth E, Raggam R, Suter A, Schoop R, Koidl C. et al . Bioavailability and pharmacokinetic studies on Echinacea purpurea preparations and their interaction with the immune system.  Int J Clin Pharm Ther. 2006;  44 401-8.
• 16 Raduner S, Majewska A, Chen J -Z, Xie X -Q, Hamon J, Faller B. et al . Alkylamides from Echinacea are a new class of cannabinomimetics - CB₂-receptor dependent and independent immunomodulatory effects.  J Biol Chem. 2006;  281 14 192-206.
• 17 Bauer R, Jurcic K, Puhlmann J, Wagner H. Immunologische in vivo- und in vitro-Untersuchungen mit Echinacea Extrakten [Immunological studies in vivo and in vitro of Echinacea extracts. Translated by Beate V Foit, Santa Cruz, CA, USA].  Arzneimittelforschung/Drug Res. 1988;  38 276-81.
• 18 Bauer R, Remiger P, Jurcic K, Wagner H. Beeinflussung der Phagozytose-Aktivität durch Echiancea-Extrakte [Influence of Echinacea extract on phagocytotic activity. Reviewed in translation, translator unknown].  Z Phytother. 1989;  10 43-8.
• 19 Rininger J A, Kickner S, Chigurupati P, McLean A, Franck Z. Immunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells.  J Leukocyte Biol. 2000;  68 503-10.
• 20 Bauer R, Jurcic K, Puhlmann J, Wagner H. Immunologische in vivo- und in vitro-Untersuchungen mit Echinacea-Extrakten.  Arzneimittelforschung. 1988;  38 276-81.
• 21 Bauer R, Remiger P, Jurcic K, Wagner H. Beeinflussung der Phagozytose-Aktivität durch Echinacea-Extrakte.  Z Phytother. 1989;  10 43-8.
• 22 Goel V, Chang C, Slama J V, Barton R, Bauer R, Gahler R. et al . Echinacea stimulates macrophage function in the lung and spleen of normal rats.  J Nutr Biochem. 2002;  13 487-92.
• 23 Goel V, Chang C, Slama J V, Barton R, Bauer R, Gahler R. et al . Alkylamides of Echinacea purpurea stimulate alveolar macrophage function in normal rats.  Int Immunopharmacol. 2002;  2 381-7.
• 24 Chen Y, Fu T, Tao T, Yang J, Chang Y, Wang M. et al . Macrophage activating effects of new alkamides from the roots of Echinacea Species.  J Nat Prod. 2005;  68 773-6.
• 25 Stevenson L M, Matthias A, Banbury L, Penman K G, Bone K M, Leach D. et al . Modulation of macrophage immune responses by Echinacea .  Molecules. 2005;  10 1279-85.
• 26 Clifford L J, Nair M G, Rana J, Dewitt D L. Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench.  Phytomedicine. 2002;  9 249-53.
• 27 Müller-Jakic B, Breu W, Pröbstle A, Redl K, Greger H, Bauer R. In vitro inhibition of cyclooxygenase and 5-lipoxygenase by alkamides from Echinacea and Achillea species.  Planta Med. 1994;  60 37-40.
• 28 Merali S, Binns S, Paulin-Levasseur M, Ficker C, Smith M, Baum B. et al . Antifungal and anti-inflammatory activity of the genus Echinacea .  Pharm Biol. 2003;  41 412-20.
• 29 Hinz B, Woelkart K, Bauer R. Alkamides from Echinacea inhibit cyclooxygenase-2-dependent prostaglandin synthesis in human neuroglioma cells.  Planta Med. 2006;  72 1062.
• 30 Woelkart K, Xu W, Pei Y, Makriyannis A, Picone R P, Bauer R. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots.  Planta Med. 2005;  71 701-5.
• 31 Sasagawa M, Cech N B, Gray D, Elmer G W, Wenner C A. Echinacea alkylamides inhibit interleukin-2 production by Jurkat T cells.  Int Immunopharmacol. 2006;  6 1214-21.
• 32 Hudson J, Vimalanathan S, Kang L, Amiguet V T, Livesey J, Arnason J T. Characterization of antiviral activities in Echinacea root preparations.  Pharm Biol. 2005;  43 790-6.
• 33 Goel V, Lovlin R, Chang C, Slama J V, Barton R, Gahler R. et al . A proprietary extract from the Echinacea plant (Echinacea purpurea) enhances systemic immune response during a common cold.  Phytother Res. 2005;  19 689-94.
• 34 Goel V, Lovlin R, Barton R, Lyon M R, Bauer R, Lee T DG. et al . Efficacy of a standardized Echinacea preparation (Echinilin^TM) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial.  J Clin Pharm Ther. 2004;  29 75-83.
• 35 Barton R. Efficacy of echinilin for the common cold.  Clin Infect Dis. 2005;  41 761-2.
• 36 Dietz B, Heilmann J, Bauer R. Absorption of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides after oral application of Echinacea purpurea tincture.  Planta Med. 2001;  67 863-4.
• 37 Jager H, Meinel L, Dietz B, Lapke C, Bauer R, Merkle H P. et al . Transport of alkamides from Echinacea species through Caco-2 monolayers.  Planta Med. 2002;  68 469-71.
• 38 Matthias A, Blanchfield J T, Penman K G, Toth I, Lang C S, De Voss J J. et al . Permeability studies of alkylamides and caffeic acid conjugates from Echinacea using a Caco-2 cell monolayer model.  J Clin Pharm Ther. 2004;  29 7-13.
• 39 Woelkart K, Koidl C, Grisold A, Gangemi J D, Turner R B, Marth E. et al . Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans.  J Clin Pharmacol. 2005;  45 683-9.
• 40 Matthias A, Addison R S, Penman K G, Dickinson R G, Bone K M, Lehmann R P. Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion.  Life Sci. 2005;  77 2018-29.
• 41 Osowski S. Echinacea - ein Immunstimulans? Zur Pharmakokinetik der Echinacea purpurea-Inhaltsstoffe Dodeca-2E,4E,8Z,10E/Z-tetraensäure-isobutylamid und Cichoriensäure sowie ihr immunmodulierender Einfluss. [dissertation]. Freiburg; Albert Ludwig University 1998.
• 42 Butterweck V, Derendorf H, Gaus W, Nahrstedt A, Schulz V, Unger M. Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate?.  Planta Med. 2004;  70 784-91.
• 43 Matthias A, Gillam E MJ, Penman K G, Matovis N J, Bone K M, De Voss J J. et al . Cytochrome P450 enzyme-mediated degradation of Echinacea alkylamides in human liver microsomes.  Chem Biol Interact. 2005;  155 62-70.
• 44 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Carrier J. et al . In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.  Clin Pharmacol Ther. 2004;  76 428-40.
• 45 Gorski J C, Huang S -M, Pinto A, Hamman M A, Hilligoss J K, Zaheer N A. et al . The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo .  Clin Pharmacol Ther. 2004;  75 89-100.
• 46 Yale S H, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2 C9.  J Altern Complement Med. 2005;  11 433-9.
• 47 Turner R B, Bauer R, Woelkart K, Hulsey T C, Gangemi J D. An evaluation of Echinacea angustifolia in experimental rhinovirus infections.  N Engl J Med. 2005;  353 341-8.
• 48 Blumenthal M, Farnsworth N R, Leach M, Turner R B, Gangemi J D. Echinacea angustifolia in rhinovirus infections (multiple letters).  N Engl J Med. 2005;  353 1971-2.